These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 12799630)

  • 21. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar.
    Taketa K; Okada S; Win N; Hlaing NK; Wind KM
    Acta Med Okayama; 2002 Dec; 56(6):317-20. PubMed ID: 12685861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma abnormal prothrombin (PIVKA-II): a new and reliable marker for the detection of hepatocellular carcinoma.
    Takikawa Y; Suzuki K; Yamazaki K; Goto T; Madarame T; Miura Y; Yoshida T; Kashiwabara T; Sato S
    J Gastroenterol Hepatol; 1992; 7(1):1-6. PubMed ID: 1371940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.
    Xu F; Zhang L; He W; Song D; Ji X; Shao J
    Dis Markers; 2021; 2021():8868370. PubMed ID: 33628341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B.
    Yang T; Xing H; Wang G; Wang N; Liu M; Yan C; Li H; Wei L; Li S; Fan Z; Shi M; Chen W; Cai S; Pawlik TM; Soh A; Beshiri A; Lau WY; Wu M; Zheng Y; Shen F
    Clin Chem; 2019 Dec; 65(12):1543-1553. PubMed ID: 31672853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
    Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
    Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
    Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.
    Wang MD; Sun LY; Qian GJ; Li C; Gu LH; Yao LQ; Diao YK; Pawlik TM; Lau WY; Huang DS; Shen F; Yang T
    Int J Surg; 2022 Sep; 105():106843. PubMed ID: 35995351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China.
    Chi X; Jiang L; Yuan Y; Huang X; Yang X; Hochwald S; Liu J; Huang H
    BMC Gastroenterol; 2022 Apr; 22(1):202. PubMed ID: 35461226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy.
    Loglio A; Iavarone M; Facchetti F; Di Paolo D; Perbellini R; Lunghi G; Ceriotti F; Galli C; Sandri MT; Viganò M; Sangiovanni A; Colombo M; Lampertico P
    Liver Int; 2020 Aug; 40(8):1987-1996. PubMed ID: 32301212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
    Abdel-Razik A; Elhelaly R; Elzehery R; El-Diasty A; Abed S; Elhammady D; Tawfik A
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):599-605. PubMed ID: 26741637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis.
    Su TH; Peng CY; Chang SH; Tseng TC; Liu CJ; Chen CL; Liu CH; Yang HC; Chen PJ; Kao JH
    J Formos Med Assoc; 2022 Mar; 121(3):703-711. PubMed ID: 34452785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The value of serum abnormal prothrombin in clinical application of hepatocellular carcinoma].
    Zhang JW; Guan LY; E CY; Yang JH; Xuan W; Meng ZH; Li W
    Zhonghua Wai Ke Za Zhi; 2020 Oct; 58(10):776-781. PubMed ID: 32993265
    [No Abstract]   [Full Text] [Related]  

  • 36. A nomogram to predict microvascular invasion in early hepatocellular carcinoma.
    Li H; Li T; Hu J; Liu J
    J Cancer Res Ther; 2021 Jul; 17(3):652-657. PubMed ID: 34269295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
    Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
    Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma.
    Gad A; Tanaka E; Matsumoto A; Wahab MA; Serwah Ael-H; Attia F; Ali K; Hassouba H; el-Deeb Ael-R; Ichijyo T; Umemura T; Muto H; Yoshizawa K; Kiyosawa K
    World J Gastroenterol; 2005 Nov; 11(42):6607-12. PubMed ID: 16425352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
    Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
    Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.